Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

18.52USD
18 Apr 2019
Change (% chg)

$-0.41 (-2.17%)
Prev Close
$18.93
Open
$18.91
Day's High
$19.02
Day's Low
$18.42
Volume
109,141
Avg. Vol
206,281
52-wk High
$27.00
52-wk Low
$10.30

Latest Key Developments (Source: Significant Developments)

D. E. Shaw & Co Reports 5.1 Percent Passive Stake In Omeros Corp As Of Feb 26, 2019
Friday, 8 Mar 2019 

March 8 (Reuters) - Omeros Corp ::D. E. SHAW & CO REPORTS A PASSIVE STAKE OF 5.1 PERCENT IN OMEROS CORP AS OF FEB 26, 2019 - SEC FILING.  Full Article

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Omeros Corp ::OMEROS FINALIZES WITH FDA CLINICAL PLAN FOR OMS721 APPROVAL IN IGA NEPHROPATHY.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL--.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL.OMEROS - OMS721 CONTINUES TO BE WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN OBSERVED.OMEROS CORP - DURING FDA MEETING, IT WAS CONFIRMED THAT PHASE 3 TRIAL'S PRIMARY ENDPOINT OF ASSESSMENT OF PROTEINURIA WILL BE EXTENDED TO 36 WEEKS.  Full Article

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023
Thursday, 8 Nov 2018 

Omeros Corp ::OMEROS ANNOUNCES PROPOSED $210 MILLION OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2023.OMEROS CORP - NOTES WILL MATURE ON NOVEMBER 15, 2023.OMEROS CORP-TO USE PORTION OF PROCEEDS OF OFFERING TO REPAY IN FULL AMOUNTS OUTSTANDING UNDER CO'S SECURED TERM LOAN AGREEMENT WITH CRG SERVICING LLC.  Full Article

Omeros Q3 Loss Per Share $0.81
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Omeros Corp ::OMEROS CORP REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.81.Q3 EARNINGS PER SHARE VIEW $-0.77 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $4.6 MILLION.Q3 REVENUE VIEW $3.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Omeros Corporation Announces Reinstatement Of Pass-Through Status For Omidria
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES REINSTATEMENT OF PASS-THROUGH STATUS FOR OMIDRIA®.OMEROS CORP - CMS' SEPARATE PAYMENT FOR CATARACT SURGERY DRUG RESUMES TODAY.OMEROS CORP - CONTINUES TO PURSUE PERMANENT SEPARATE PAYMENT FOR OMIDRIA..OMEROS CORP - CONTINUES TO PURSUE PERMANENT SEPARATE PAYMENT FOR OMIDRIA.  Full Article

Omeros’ OMS721 Receives European Orphan Drug Designation
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Omeros Corp ::OMEROS’ OMS721 RECEIVES EUROPEAN ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR TREATMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION.OMEROS CORP - DISCUSSIONS ONGOING WITH EUROPEAN REGULATORS FOR PATHWAY TO EXPEDITED APPROVAL.OMEROS CORP - POSITIVE OPINION EXPECTED TO BE ADOPTED BY EUROPEAN COMMISSION IN AUGUST.OMEROS CORP - INITIATED MANUFACTURING SCALE-UP PROCESS OF ITS MASP-3 ANTIBODIES IN PREPARATION FOR CLINICAL TRIALS.  Full Article

Omeros Corp Initiates Sales Of Omidria In Europe
Monday, 23 Jul 2018 

July 23 (Reuters) - Omeros Corp ::OMEROS CORPORATION INITIATES SALES OF OMIDRIA® IN EUROPE.OMEROS SAYS THESE INITIAL SALES OF OMIDRIA (PHENYLEPHRINE & KETOROLAC INTRAOCULAR SOLUTION) 1 PCT/0.3 PCT IN EUROPE SATISFY "SUNSET CLAUSE" PROVISION IN EU.  Full Article

FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721
Thursday, 26 Apr 2018 

April 26 (Reuters) - Omeros Corp ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.DISCUSSIONS ONGOING WITH FDA AND EUROPEAN REGULATORS FOR EXPEDITED APPROVAL OF OMS721.  Full Article

Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Omeros Corp ::OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORP - ‍INITIATES OMS721 PHASE 3 PROGRAM IN HCT-TMA​.OMEROS CORP - ‍ PATIENT ENROLLMENT FOR ITS PHASE 3 CLINICAL TRIAL EVALUATING OMS721 IN PATIENTS WITH IGA NEPHROPATHY IS EXPECTED TO BEGIN EARLY IN FEB.  Full Article

Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS.FDA APPROVED SNDA FOR OMIDRIA UNDER PRIORITY REVIEW.  Full Article